GlobeNewswire: EDAP TMS S.A. Contains the last 10 of 398 releaseshttp://www.globenewswire.com/External?Length=42024-03-29T14:32:53ZGlobeNewswirehttp://www.globenewswire.com/External?Length=4newsdesk@globenewswire.com (NewsDesk)https://www.globenewswire.com/news-release/2024/03/27/2853035/0/en/EDAP-Reports-Fourth-Quarter-and-Full-Year-2023-Financial-Results.html?f=22&fvtc=4&fvtv=7538EDAP Reports Fourth Quarter and Full-Year 2023 Financial Results2024-03-27T11:00:00Z<![CDATA[LYON, France, March 27, 2024 - EDAP TMS SA (Nasdaq: EDAP), the global leader in robotic energy-based therapies, reported today unaudited financial results for the fourth quarter and full-year 2023.]]>https://www.globenewswire.com/news-release/2024/03/13/2845298/0/en/EDAP-to-Announce-Fourth-Quarter-and-Full-Year-2023-Financial-Results-on-March-27-2024.html?f=22&fvtc=4&fvtv=7538EDAP to Announce Fourth Quarter and Full-Year 2023 Financial Results on March 27, 20242024-03-13T11:00:00Z<![CDATA[Company to host conference call and webcast on Wednesday, March 27th at 8:30am EDT]]>https://www.globenewswire.com/news-release/2024/03/06/2841240/0/en/EDAP-to-Present-at-the-Oppenheimer-34th-Annual-Healthcare-MedTech-Services-Conference.html?f=22&fvtc=4&fvtv=7538EDAP to Present at the Oppenheimer 34th Annual Healthcare MedTech & Services Conference2024-03-06T12:00:00Z<![CDATA[LYON, France, March 6, 2024 -- EDAP TMS SA (Nasdaq: EDAP) (“the Company”), the global leader in robotic energy-based therapies, today announced that Ryan Rhodes, Chief Executive Officer, is scheduled to deliver a virtual presentation and host 1x1 investor meetings at the Oppenheimer 34th Annual Healthcare MedTech & Services Conference, which is being held virtually from March 12-13, 2024.]]>https://www.globenewswire.com/news-release/2024/03/04/2839402/0/en/EDAP-Announces-FDA-Breakthrough-Device-Designation-for-Focal-One-in-the-Treatment-of-Deep-Infiltrating-Rectal-Endometriosis.html?f=22&fvtc=4&fvtv=7538EDAP Announces FDA Breakthrough Device Designation for Focal One® in the Treatment of Deep Infiltrating Rectal Endometriosis2024-03-04T12:00:00Z<![CDATA[Focal One HIFU has potential to address large market impacting thousands of women each year]]>https://www.globenewswire.com/news-release/2024/02/29/2837820/0/en/EDAP-Announces-Record-Preliminary-Fourth-Quarter-and-Full-Year-2023-Revenues.html?f=22&fvtc=4&fvtv=7538EDAP Announces Record Preliminary Fourth Quarter and Full-Year 2023 Revenues2024-02-29T12:00:00Z<![CDATA[LYON, France, February 29, 2024 - EDAP TMS SA (Nasdaq: EDAP), a global leader in robotic energy-based therapies, today announced preliminary unaudited fourth quarter and full-year 2023 revenues.]]>https://www.globenewswire.com/news-release/2024/02/01/2821937/0/en/EDAP-Announces-Completion-of-Enrollment-in-Phase-3-Study-Evaluating-Focal-One-HIFU-Therapy-for-the-Treatment-of-Deep-Infiltrating-Rectal-Endometriosis.html?f=22&fvtc=4&fvtv=7538EDAP Announces Completion of Enrollment in Phase 3 Study Evaluating Focal One HIFU Therapy for the Treatment of Deep Infiltrating Rectal Endometriosis2024-02-01T13:00:00Z<![CDATA[LYON, France, February 1, 2024 - EDAP TMS SA (Nasdaq: EDAP), the global leader in robotic energy-based therapies, announced today that it has completed enrollment in its Phase 3 study (Endo-HIFU-R2) evaluating Focal One High-Intensity Focused Ultrasound (HIFU) therapy for the treatment of deep infiltrating rectal endometriosis. The ongoing Phase 3 study (NCT05755958) is a comparative, randomized, double blind trial, with the primary objective of evaluating acute pelvic pain levels in 60 patients. Select treated patients are followed three months post-HIFU treatment in comparison to a sham group. The last patient was treated in January. Study results are expected in the second half of 2024.]]>https://www.globenewswire.com/news-release/2024/01/08/2805370/0/en/EDAP-Announces-Preliminary-Fourth-Quarter-Record-Focal-One-System-Sales-and-Placements.html?f=22&fvtc=4&fvtv=7538EDAP Announces Preliminary Fourth Quarter Record Focal One® System Sales and Placements2024-01-08T13:00:00Z<![CDATA[Company reports preliminary placement results of twelve Focal One Systems, inclusive of ten capital sales]]>https://www.globenewswire.com/news-release/2024/01/02/2802606/0/en/EDAP-Appoints-Ken-Mobeck-Global-Chief-Financial-Officer-and-Francois-Dietsch-Global-Chief-Accounting-Officer.html?f=22&fvtc=4&fvtv=7538EDAP Appoints Ken Mobeck, Global Chief Financial Officer, and Francois Dietsch, Global Chief Accounting Officer2024-01-02T13:00:00Z<![CDATA[]]>https://www.globenewswire.com/news-release/2023/12/12/2794688/0/en/EDAP-Announces-Positive-Opinion-for-Reimbursement-from-the-French-National-Authority-for-Health-HAS-for-HIFU-treatment-of-Prostate-Cancer.html?f=22&fvtc=4&fvtv=7538EDAP Announces Positive Opinion for Reimbursement from the French National Authority for Health (HAS) for HIFU treatment of Prostate Cancer2023-12-12T13:00:00Z<![CDATA[Represents Key Milestone Toward Universal Coverage for Focal One HIFU in France]]>https://www.globenewswire.com/news-release/2023/12/06/2792122/0/en/EDAP-Appoints-Lance-Willsey-M-S-M-D-to-Board-of-Directors.html?f=22&fvtc=4&fvtv=7538EDAP Appoints Lance Willsey, M.S., M.D. to Board of Directors2023-12-06T21:30:00Z<![CDATA[LYON, France, December 6, 2023 -- EDAP TMS SA (Nasdaq: EDAP) (“the Company” or “EDAP”), the global leader in robotic energy-based therapies, today announced the appointment of Lance Willsey, M.S., M.D. to its Board of Directors. Dr. Willsey replaces Dr. Argil Wheelock who has resigned as director of the Company.]]>